Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19

医学 随机对照试验 肝素 人口 临床试验 治疗指标 重症监护医学 内科学 急诊医学 药理学 环境卫生 药品
作者
Ewan C. Goligher,Patrick R. Lawler,Thomas P. Jensen,Victor B. Talisa,Lindsay R. Berry,Elizabeth Lorenzi,Bryan J. McVerry,Chung‐Chou Ho Chang,Eric Leifer,Charlotte Bradbury,Jeffrey S. Berger,B. J. Hunt,Lana A. Castellucci,Lucy Z. Kornblith,Anthony Gordon,Colin McArthur,Steven Webb,Judith S. Hochman,Matthew D. Neal,Ryan Zarychanski
出处
期刊:JAMA [American Medical Association]
卷期号:329 (13): 1066-1066 被引量:97
标识
DOI:10.1001/jama.2023.3651
摘要

Importance: Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity of treatment effect (HTE) across individuals. Better understanding of HTE could facilitate individualized clinical decision-making. Objective: To evaluate HTE of therapeutic-dose heparin for patients hospitalized for COVID-19 and to compare approaches to assessing HTE. Design, Setting, and Participants: Exploratory analysis of a multiplatform adaptive RCT of therapeutic-dose heparin vs usual care pharmacologic thromboprophylaxis in 3320 patients hospitalized for COVID-19 enrolled in North America, South America, Europe, Asia, and Australia between April 2020 and January 2021. Heterogeneity of treatment effect was assessed 3 ways: using (1) conventional subgroup analyses of baseline characteristics, (2) a multivariable outcome prediction model (risk-based approach), and (3) a multivariable causal forest model (effect-based approach). Analyses primarily used bayesian statistics, consistent with the original trial. Exposures: Participants were randomized to therapeutic-dose heparin or usual care pharmacologic thromboprophylaxis. Main Outcomes and Measures: Organ support-free days, assigning a value of -1 to those who died in the hospital and the number of days free of cardiovascular or respiratory organ support up to day 21 for those who survived to hospital discharge; and hospital survival. Results: Baseline demographic characteristics were similar between patients randomized to therapeutic-dose heparin or usual care (median age, 60 years; 38% female; 32% known non-White race; 45% Hispanic). In the overall multiplatform RCT population, therapeutic-dose heparin was not associated with an increase in organ support-free days (median value for the posterior distribution of the OR, 1.05; 95% credible interval, 0.91-1.22). In conventional subgroup analyses, the effect of therapeutic-dose heparin on organ support-free days differed between patients requiring organ support at baseline or not (median OR, 0.85 vs 1.30; posterior probability of difference in OR, 99.8%), between females and males (median OR, 0.87 vs 1.16; posterior probability of difference in OR, 96.4%), and between patients with lower body mass index (BMI <30) vs higher BMI groups (BMI ≥30; posterior probability of difference in ORs >90% for all comparisons). In risk-based analysis, patients at lowest risk of poor outcome had the highest propensity for benefit from heparin (lowest risk decile: posterior probability of OR >1, 92%) while those at highest risk were most likely to be harmed (highest risk decile: posterior probability of OR <1, 87%). In effect-based analysis, a subset of patients identified at high risk of harm (P = .05 for difference in treatment effect) tended to have high BMI and were more likely to require organ support at baseline. Conclusions and Relevance: Among patients hospitalized for COVID-19, the effect of therapeutic-dose heparin was heterogeneous. In all 3 approaches to assessing HTE, heparin was more likely to be beneficial in those who were less severely ill at presentation or had lower BMI and more likely to be harmful in sicker patients and those with higher BMI. The findings illustrate the importance of considering HTE in the design and analysis of RCTs. Trial Registration: ClinicalTrials.gov Identifiers: NCT02735707, NCT04505774, NCT04359277, NCT04372589.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
共享精神的应助被Erpan采纳,获得10
1秒前
1秒前
彭于晏的应助被Lynn采纳,获得10
1秒前
Holic完成签到,获得积分10
2秒前
zyy发布了新的文献求助10
3秒前
4秒前
yy发布了新的文献求助10
4秒前
焦小黑发布了新的文献求助10
5秒前
5秒前
xiaoluoluo完成签到,获得积分10
5秒前
斯文败类的应助被科研小白采纳,获得10
5秒前
终梦的应助被辛酸有很多种采纳,获得20
5秒前
fanfan发布了新的文献求助10
6秒前
chai完成签到,获得积分10
7秒前
zlll完成签到 ,获得积分10
7秒前
乐天完成签到 ,获得积分10
8秒前
大喜完成签到,获得积分10
8秒前
8秒前
水煮电吹风的应助被hsj采纳,获得10
9秒前
xsx1111完成签到,获得积分10
9秒前
cloud云完成签到,获得积分10
10秒前
10秒前
向大闹闹发布了新的文献求助10
11秒前
燕燕完成签到 ,获得积分10
11秒前
12秒前
哇哇大叫发布了新的文献求助10
12秒前
Tang发布了新的文献求助10
13秒前
hsj完成签到,获得积分10
13秒前
13秒前
serendipity完成签到,获得积分10
13秒前
13秒前
流苏发布了新的文献求助10
14秒前
搜集达人的应助被Yutong采纳,获得10
14秒前
15秒前
可可完成签到,获得积分10
15秒前
Erpan发布了新的文献求助10
15秒前
HaoruMeng完成签到,获得积分10
15秒前
打打的应助被zyy采纳,获得30
15秒前
hnu301发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181940
求助须知:如何正确求助?哪些是违规求助? 9571697
关于积分的说明 21819181
捐赠科研通 7778330
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557767
邀请新用户注册赠送积分活动 2479621